65095-33-2

Basic information

• Product Name: Ethanone, 1-(4-bromo-2-methylphenyl)-
• Synonyms: Ethanone, 1-(4-bromo-2-methylphenyl)-;1-(4-Bromo-2-methylphenyl)ethanone;4'-Bromo-2'-methylacetophenone;1-(4-Bromo-2-methylphenyl)
• CAS NO: 65095-33-2
• Molecular Formula: C₉H₉BrO
• Molecular Weight: 213.07
• Product Categories: API intermediates
• Mol File: 65095-33-2.mol

Chemical Properties

• Boiling Point: 278 °C
• Flash Point: 85 °C
• Appearance: /
• Density: 1.388
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Ethanone, 1-(4-bromo-2-methylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(4-bromo-2-methylphenyl)-(65095-33-2)
• EPA Substance Registry System: Ethanone, 1-(4-bromo-2-methylphenyl)-(65095-33-2)

Safety Data

• Hazardous Substances Data: 65095-33-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 1-(4-bromo-2-methylphenyl)is used as an intermediate for the synthesis of pharmaceuticals, contributing to the development of various medicinal compounds.
Used in Agrochemical Industry:
This chemical serves as an intermediate in the synthesis of agrochemicals, playing a role in the production of substances used in agriculture to manage pests and enhance crop yields.
Used in Organic Synthesis:
Ethanone, 1-(4-bromo-2-methylphenyl)is utilized as a precursor in organic synthesis, facilitating the creation of a diverse range of chemical products.
Used in Preparation of Functionalized Compounds:
As a building block, this chemical is instrumental in the preparation of a wide array of functionalized compounds, expanding the scope of chemical research and application.

Upstream product

• 7446-70-0 aluminium trichloride 
• 591-17-3 meta-bromotoluene 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 
• 67832-11-5 4-bromo-2-methylbenzonitrile 
• 75-16-1 methylmagnesium bromide 
• 917-64-6 methyl magnesium iodide 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 676-58-4 methylmagnesium chloride 
• 178313-45-6 4-bromo-N-methoxy-N,2-dimethylbenzamide 
• 917-54-4 methyllithium 

Downstream Products

• 1616930-59-6 C₁₄H₁₅BrN₂O₂ 
• 1616930-60-9 C₁₇H₁₇N₃O₂S 
• 1616930-58-5 C₁₃H₁₃BrO₄ 
• 1393537-68-2 C₃₉H₅₀N₂O₁₀ 

Relevant articles and documents

CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE

Provided are compounds of Formula (I): Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, A1, B1, B2, Q1 and Q2 are as defined herein; and methods for their use and production.

INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Pyrazolyl-Based Carboxamides I

The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

PYRAZOLYL-BASED CARBOXAMIDES I AS CRAC CHANNEL INHIBITORS

The Invention relates to pyrazolyl-based carboxamide compounds of formula (l) useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds of formula I, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in th

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection of following Fomula (I). Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

SUBSTITUTED HYDANTOINS

The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.